BETHESDA, Md., April 22, 2013 /PRNewswire/ -- TNI BioTech, Inc. (OTC Pink: TNIB) (www.tnibiotech.com), announced it has filed its Form 10 to become a fully reporting public company with the Securities and Exchange Commission.
Some of the highlights of the filing are the acquisition and licensing agreements between TNI BioTech and Dr. Nicholas P. Plotnikoff , Dr. Bernard Bihari , Professor Fengping Shan , Dr. Jill Smith and LDN Research LLC, and Pennsylvania State University. In addition to the patents and licenses, TNI BioTech has obtained the rights to the clinical data and the transfer of the Investigation New Drug (IND) and orphan drug designations from the U.S. Food & Drug Administration for pancreatic cancer and Crohn's disease. TNI BioTech believes the orphan drug designations will allow the company to fast track the development of clinical trials for both of these indications in the United States and internationally.
"We are fortunate to have such expert and dedicated leadership in key positions here at TNI BioTech and our affiliate companies," stated Noreen Griffin , CEO of TNI BioTech. "The last few weeks have been a test of our resolve, and we have demonstrated that we are up for the challenge in running a public company." The Form 10 document, financial statements, auditor's footnotes, and opinion letter can be found at the following link on the company's website http://www.tnibiotech.com/investor-relations/tnib-form-10-2013
About TNI BioTech, Inc.
TNI BioTech Inc. is a biotech company with the goal of benefitting patients with chronic and often life-threatening diseases through the activati
|SOURCE TNI BioTech, Inc.|
Copyright©2012 PR Newswire.
All rights reserved